Core Insights - Enveric Biosciences Inc. (NASDAQ:ENVB) shares experienced a significant increase of 73.82% in after-hours trading, reaching a price of $10.29, following a closing price of $5.92, which was down 2.47% on the same day [1]. Patent Announcement - The company received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application related to its EVM301 Series molecules, aimed at potential treatments for mental health disorders [2]. - The patent titled "N-heterocycle substituted tryptamine derivatives and methods of using" includes claims that could broaden Enveric's pipeline by covering additional neuroplastogenic, non-hallucinogenic molecules for treating neuropsychiatric and addiction disorders [3]. Product Development - The patent is expected to strengthen Enveric's EVM301 Series portfolio, which features its lead asset, EB-003, a non-hallucinogenic serotonin receptor agonist under development for depressive and anxiety disorders [4]. Company Strategy - Joseph Tucker, Director and CEO of Enveric, emphasized the importance of reinforcing the patent estate around EB-003 and the EVM301 Series of compounds to generate value for shareholders [5]. Stock Performance - Despite the recent surge, ENVB stock has seen a substantial decline of 91.57% year-to-date, with a market capitalization of $3.45 million and an annual trading range between $4.88 and $96.30 [5]. - Benzinga Edge Stock Rankings indicate a negative price trend for ENVB across all time frames [6].

As filed with the Securities and Exchange Commission on December 1, 2023 Registration No. 333-275380 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2834 95-4484725 (I.R.S. Employer Identificati ...